Formulations for respiratory tract administration

a technology for respiratory tracts and formulations, applied in the direction of aerosol delivery, drug compositions, peptide/protein ingredients, etc., can solve the problems of slow and variable rate of analgesia onset, complicating use, and inability to conveniently administer certain patients, so as to improve flow properties and dispensing accuracy, the effect of easy elimination
US20010049391A1Inactive Publication Date: 2001-12-06ALFONSO MARK +2

Patent Information

Authority / Receiving Office
US ยท United States
Patent Type
Applications(United States)
Current Assignee / Owner
ALFONSO MARK
Publication Date
2001-12-06
Estimated Expiration
Not applicable ยท inactive patent
Patent Text Reader

Abstract

A dosage form for intranasal and / or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and / or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to formulations and methods for the intranasal and inhalation administration of analgesics having low opioid receptor binding affinity.

[0002] Pharmacologically active compounds are most commonly administered by the oral route. In particular, analgesics are preferably taken by mouth. However, this convenient route of administration is not always possible for certain patients. Contraindications to oral administration of analgesics can include nausea and / or emesis, oral or gastrointestinal surgery and dysphagia. In addition, rate of analgesia onset is slower and more variable due to first pass effects which compromise the apparent potency of some analgesics and complicate their use. The alternative of administration by injection, e.g., parenteral, intramuscular or subcutaneous injection, is generally not preferred due to patient discomfort and the attendant increased costs associated with the production of and administration of injectable products.[...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More